Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

INTRODUCTION: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley, Samad, Ahmed, Karis, Elaine, Stolshek, Bradley S., Trivedi, Mona, Zhang, Hao, Aras, Girish A., Kricorian, Greg, Chung, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514022/
https://www.ncbi.nlm.nih.gov/pubmed/30915626
http://dx.doi.org/10.1007/s40744-019-0152-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514022/
https://www.ncbi.nlm.nih.gov/pubmed/30915626
http://dx.doi.org/10.1007/s40744-019-0152-8

Ejemplares similares